OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
暂无分享,去创建一个
G R Wilkinson | R. Kim | M. Fromm | G. Wilkinson | B. Leake | R B Kim | M. Cvetković | B Leake | M F Fromm | M Cvetkovic | M. Cvetkovic
[1] G R Wilkinson,et al. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.
[2] P. Meier,et al. The Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver* , 1998, The Journal of Biological Chemistry.
[3] P. Meier,et al. Substrate specificity of the rat liver Na+-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. , 1998, American journal of physiology. Gastrointestinal and liver physiology.
[4] D. Roden,et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.
[5] P. Meier,et al. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[6] M. Kool,et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.
[7] J. Beijnen,et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[8] Piet Borst,et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein , 1996, British journal of pharmacology.
[9] P. Meier,et al. The peptide‐based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion‐transporting polypeptide , 1996, Hepatology.
[10] A. Schinkel,et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.
[11] P. Meier,et al. Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. , 1996, The Journal of pharmacology and experimental therapeutics.
[12] P. Meier,et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. , 1995, Gastroenterology.
[13] P. Borst,et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.
[14] V. Ling,et al. Identification of a sister gene to P-glycoprotein. , 1995, Cancer research.
[15] D. Levêque,et al. P-glycoprotein and pharmacokinetics. , 1995, Anticancer research.
[16] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[17] P. Meier,et al. Expression cloning of a rat liver Na(+)-independent organic anion transporter. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[18] Y Chen,et al. Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.
[19] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[20] G. Mickisch. Multidrug Resistance , 1996, Der Urologe A.
[21] F. Warner. Analysis of expression. , 1885 .